Purchase the ATMP report at www.evernowpublishing.com

Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.

The latest MedNous journal. Subscribe to download.

New cholesterol drug is approved

Country: United States

Repatha (evolocumab), a new drug for lowering cholesterol in patients with cardiovascular disease or familial hypercholesterolemia, has been approved by the Food and Drug Administration. Developed by Amgen, the drug received a positive opinion from the European Medicines Agency in May.

Read more

US footprint for Immatics

Country: Germany

Germany-based Immatics Biotechnologies GmbH has launched a subsidiary in the US with the support of the MD Anderson Cancer Center in order to develop adoptive cellular therapies for the treatment of a range of cancers.

Read more

Merus obtains financing

Country: Netherlands

Read more

Valeant to acquire Sprout for $1 billion

Country: United States

Read more

New drug for sexual desire disorder

Country: United States

Read more

How prions travel to the brain

Country: United Kingdom

Read more

Biomarker for breast cancer

Country: United States

Read more

Ebola virus’ strength linked to cholesterol

Country: Germany

Read more

Merck, MD Anderson to work on solid tumours

Country: United States

Read more

Venetoclax study meets endpoint - Roche

Country: Switzerland

Read more

New insight into blood pressure

Country: Germany

Read more

Evotec reports strong revenue growth

Country: Germany

Read more

Looking for more?

Visit our news section for more articles.

News
Our full Mednous news archive
Appointments
Latest industry appointments
Events
A list of upcoming industry events

About Mednous

MedNous is a print publication and a website for everyone involved in medical research in Europe.

Read more

Free Article

The sky is the limit as Celgene invests in Juno

CommentaryStéphaneBoisselJulAug15.pdf

Highlights of the July-August 2015 MedNous issue

The July-August 2015 MedNous features:

Latest Mednous cover
  • Business Strategy
    Antibodies for infectious disease
    Interview with Humabs
  • Public Policy
    Controversy over the ‘hospital exemption’
  • Commentary
    The new deal in immunotherapy: Celgene and Juno
    By Stéphane Boissel
  • Commentary
    Has the UK helped Biotech SMEs?
    by Jon Rees
  • Quarterly stock market review
    Big gains for eight European biotechs

The latest MedNous journal. Subscribe to download.